

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/031,509	10/031,509 05/21/2002		Eric Paul Krenning	0702-020040	6829
28289	7590	05/18/2006		EXAMINER	
		FIRM, P.C.	HUI, SAN MING R		
700 KOPPE 436 SEVEN				ART UNIT	PAPER NUMBER
PITTSBUR			1617		
				DATE MAILED, 05/19/200	2

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)					
		10/031,509	KRENNING ET AL.					
	Office Action Summary	Examiner	Art Unit					
		San-ming Hui	1617					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
WHIC - Exter after - If NO - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING Donsions of time may be available under the provisions of 37 CFR 1.1 SIX (6) MONTHS from the mailing date of this communication. Period for reply is specified above, the maximum statutory period ver to reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDON	ON. timely filed m the mailing date of this communication. IED (35 U.S.C. § 133).					
Status								
2a)⊠	Since this application is in condition for allowar	action is non-final. nce except for formal matters, p						
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.								
Disposition of Claims								
5)□ 6)⊠ 7)□	Claim(s) 53,55-58 and 60-63 is/are pending in 4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed. Claim(s) 53,55-58 and 60-63 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and/or	wn from consideration.						
Applicati	ion Papers							
10)	The specification is objected to by the Examine The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Ex	epted or b) objected to by the drawing(s) be held in abeyance. Stion is required if the drawing(s) is c	ee 37 CFR 1.85(a). objected to. See 37 CFR 1.121(d).					
Priority (ınder 35 U.S.C. § 119							
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 								
2) Notic 3) Inform	t(s) te of References Cited (PTO-892) te of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) r No(s)/Mail Date	4) Interview Summal Paper No(s)/Mail 5) Notice of Informal 6) Other:						

Application/Control Number: 10/031,509

Art Unit: 1617

DETAILED ACTION

Applicant's amendments filed March 6, 2006 have been entered.

Claims 53, 55-58, and 60-63 are pending.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 53, 55-58, and 60-63 are stand rejected under 35 U.S.C. 103(a) as being unpatentable over US 5,648,059 ('059), US 5,843,894 ('894) and Hammond et al. (Br. J. Cancer, 1993;67:1437-1439) from IDS filed April 21, 2003), for the same reason of record.

Response to Arguments

Applicant's arguments filed March 6, 2006 averring the recited transitional phrase "consisting essentially of" obviating the outstanding rejection have been fully considered but they are not persuasive. Although Hammond teaches other amnio acids to be administered, the essential active ingredients, as taught by the cited prior arts as a whole, are lysine, or polylysine, and arginine. The cited prior arts as a whole provide motivation to one of ordinary skill in the art to employ essentially lysine or polylysine with argnine. Furthermore, the dosage of the amino acids employed is taught in the

Application/Control Number: 10/031,509

Art Unit: 1617

cited prior arts. Therefore, possessing the teachings of the cited prior arts, one of ordinary skill in the art would have employed the herein claimed amino acids in a method of inhibiting renal uptake of proteins and peptides.

Applicant's arguments filed March 6, 2006 averring the cited prior arts' failure to provide motivation to co-administration of herein claimed amino acids have been considered, but are not found persuasive. The cited prior arts as a whole clearly teach what amino acids are essential in inhibiting antibodies and peptides in renal uptake. '059 even teaches the co-administration of lysine or polylysine with arginine (See claim 5). Possessing the teachings of the cited prior arts, one of ordinary skill in the art would therefore be motivated to employ the herein claimed amino acids in a method of inhibiting renal uptake of proteins and peptides, absent evidence to the contrary.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Application/Control Number: 10/031,509

Art Unit: 1617

6:00.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to San-ming Hui whose telephone number is (571) 272-0626. The examiner can normally be reached on Mon 9:00 to 1:00, Tu - Fri from 9:00 to

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, PhD., can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

San-ming Høi Primary Examiner Art Unit 1617 Page 4